The spooky reason for the grave window was shared by a TikTok user. Source: TikTok/bobbiecurtislee
Bills lineman Cody Ford was fined for this block, which NFL officials now say is perfectly legal.
TH1902 anti-tumor post-treatment effect persists longer than with docetaxel aloneMONTREAL, April 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new in vivo preclinical data were presented at the 2021 Annual Meeting of the American Association for Cancer Research (AACR). These data demonstrated sustained tumor regression, better anti-tumor activity and tolerability with TH1902 compared to docetaxel alone in all cancer types studied, namely melanoma, pancreatic, ovarian, endometrial, colorectal and triple-negative breast cancers. The anti-tumor effect of TH1902 persisted longer post-treatment than with docetaxel alone. TH1902 is the Company’s lead investigational peptide-drug conjugate (PDC) derived from its SORT1+ Technology™. “The FDA fast-track designation for TH1902 was supported by the data presented today. This designation is a significant recognition of our SORT1+ Technology™ as very few investigational therapies receive fast track designation based on preclinical data. It strongly endorses TH1902 as a potentially new and innovative treatment for all patients with sortilin positive (SORT1+) solid tumors that are refractory to standard therapy. The Phase 1 clinical trial is now underway and we look forward to advancing TH1902 through further stages of its development,” said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies. AACR Poster #1313 – TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several SORT1+ cancersHighlights of the poster include new data on TH1902 in melanoma, where the sortilin receptor is expressed in over 90% of cases. TH1902 was associated with superior anti-tumor effect and sustained post-treatment effect compared to docetaxel alone. Other highlights of this poster include better and sustained anti-tumor effect in pancreatic tumors, where sortilin is expressed in 30% to 50% of cases and in triple-negative breast cancer, where sortilin is expressed in almost 60% of cases. Treatment effect was also observed with TH1902 in colorectal cancer, which is encouraging as docetaxel is not recognized as standard of care due to lack of response in this cancer. The positive effect of TH1902 on tumor regression was also observed in these cancer types at an equimolar quarter dose compared to docetaxel alone. Only registered attendees can access the poster. AACR Poster #1439 – Increasing potency of anticancer drugs through SORT1+ Technology™: A new targeted approach for treatment of ovarian and endometrial cancers New data presented in this poster demonstrated sustained inhibition of ovarian and endometrial cancers with TH1902 at equimolar doses of docetaxel alone. Specifically, TH1902 showed improved anti-tumor activity in endometrial cancer at an equimolar quarter doses compared to docetaxel alone. Sortilin is expressed in over 90% of ovarian and endometrial cancers, making it an excellent target for drug development. Ovarian and endometrial cancers have poor prognosis and survival outcomes. Sortilin expression increases as a function of tumor grade (I to IV) and is associated with poor prognosis and decreased survival in different cancers. Only registered attendees can access the poster. Absence of neutropenia with TH1902Neutropenia was absent after six consecutive treatments with TH1902 at an equivalent dose of the maximum tolerated dose (MTD) of docetaxel, whereas a single treatment of docetaxel strongly reduced neutrophil counts. Neutropenia increases susceptibility to develop infections. Several cancer treatments are known to cause neutropenia and require on and off treatment cycles to avoid the potentially severe consequences of infections associated with the onset of neutropenia. Phase 1 clinical trial of TH1902The Phase 1 dose-escalating study is evaluating the safety, pharmacokinetics, maximum tolerated dose (MTD) and preliminary anti-tumor activity of TH1902 administered once every three weeks in patients with advanced solid tumors refractory to available anti-cancer therapies. Once the MTD is determined, it is planned that a total of 40 additional patients will be enrolled to evaluate the potential anti-tumor activity of TH1902 in patients with endometrial, ovarian, colorectal, pancreatic and triple negative breast cancers. The detailed Phase 1 study protocol is available at ClinicalTrials.gov under the identifier number: NCT04706962. About TH1902TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. This PDC is the lead candidate derived from Theratechnologies’ SORT1+ Technology™ in oncology. The Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), will contribute a total of 1.4 million dollars towards some of the research currently being conducted for the development of Theratechnologies’ targeted oncology platform at the molecular oncology laboratory of Dr Borhane Annabi at the Université du Québec in Montréal (UQAM). About SORT1+ Technology™ Theratechnologies has developed a peptide which specifically targets sortilin (SORT1) receptors. SORT1 is expressed in ovarian, triple negative breast, skin, lung, colorectal and pancreatic cancers, among others. SORT1 plays a significant role in protein internalization, sorting and trafficking, making it an attractive target for drug development. Commercially available anticancer drugs, like docetaxel, doxorubicin or tyrosine kinase inhibitors are conjugated to Theratechnologies’ investigational novel peptide to specifically target sortilin receptors. This could potentially improve the efficacy and safety of those agents. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-Looking Information This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the development of TH1902 for the potential treatment for all patients with sortilin positive (SORT1+) solid tumors that are refractory to standard therapy, and the determination of the MTD. Forward-looking statements are based upon a number of assumptions and include, but are not limited to, the following: pre-clinical in vivo results will be replicated in humans during the Phase 1 trial, we will be able to determine the MTD, we will be able to enroll patients for the Phase 1 trial, treatment with TH1902 will be efficacious and safe in various types of cancer and no serious adverse side effects will be discovered from the administration of TH1902 to patients. Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release. These risks and uncertainties include, among others, the risk that the Covid-19 pandemic will materially adversely affect the conduct of our Phase 1 trial, we are unable to determine the MTD, results obtained from the administration of TH1902 do not allow the pursuit of additional clinical trials, patients die and such death is related to the administration of TH1902 resulting in the abandonment of our Phase 1 trial, discovery of serious adverse side effects also leading to the abandonment of the Phase 1 trial, difficulty in recruiting patients leading to delays in initiating or completing the Phase 1 trial and non-performance by our third-party contract suppliers of their covenants, obligations or undertakings under the terms of our agreements with them. We refer potential investors to the "Risk Factors" section of our annual information form dated February 24, 2021 available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov as an exhibit to our report on Form 40-F dated February 25, 2021 under Theratechnologies’ public filings for additional risks regarding the conduct of our business and Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. For media inquiries:Denis BoucherVice President, Communications and Corporate Affairs514-336-7800communications@theratech.com For investor inquiries:Leah GibsonSenior Director, Investor Relations617-356-1009ir@theratech.com
With that in mind, here are a few key pieces of information you should have if you'll be applying for a mortgage in the near term. Mortgage lenders generally require a minimum credit score of 620 for a conventional home loan. Also, the higher your score, the better the interest rate you're apt to snag on your mortgage.
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of XL Fleet Corp. (NYSE: XL) between October 2, 2020 and March 2, 2021, inclusive (the “Class Period”), of the important May 7, 2021 lead plaintiff deadline. SO WHAT: If you purchased XL Fleet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the XL Fleet class action, go to http://www.rosenlegal.com/cases-register-2055.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 7, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) XL Fleet’s salespeople were pressured to inflate their sales pipelines to boost the Company’s reported sales and backlog; (2) at least 18 of the 33 customers that XL Fleet featured were inactive and had not placed an order since 2019; (3) XL Fleet’s technology had been materially overstated and offered only 5% to 10% of fleet savings; (4) XL Fleet lacks the supply chain and engineers to roll out new products on the announced timeline; and (5) as a result of the foregoing, defendants’ positive statements about XL Fleet’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the XL Fleet class action, go to http://www.rosenlegal.com/cases-register-2055.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com cases@rosenlegal.com www.rosenlegal.com
In today's video, I look at four fintech stocks that could benefit from the movement of digital banking. In early April, JPMorgan Chase (NYSE: JPM) sent out its annual shareholder letter. Having a big bank admit that the threat from fintech companies is real pushed some of those stock prices up.
WWE has announced that it's created its first-ever NFTs.
(Bloomberg) -- Surging cases in the Midwest helped push the number of daily U.S. infections to their highest in more than two weeks as the nation’s vaccination push gathers pace. European Union officials said the bloc is overcoming its vaccine supply problem and may have 70% of adults fully inoculated before the end of July, raising the prospect of an almost normal tourism season. Vaccines are in shorter supply in India, as the world’s second most populous country confronts a second wave. Thailand’s infection rate reached the highest since February and Japan is imposing restrictions in Tokyo and other cities to rein in the rapid spread of the virus. Key Developments:Global Tracker: Cases pass 134.7 million; deaths 2.91 millionVaccine Tracker: More than 748 million shots given worldwideIndia’s hospitals swamped by second virus wave as shots run lowWHO chief says political will is missing for equitable vaccinationU.K. urges mourners not to gather after death of Prince PhilipEurope finds some rare successes in its struggle to defeat CovidChina’s bid to ramp up vaccinations hindered by supply shortagesSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click CVID on the terminal for global data on cases and deaths.U.S. Cases Continue to Accelerate (8 a.m. NY)The U.S. added almost 81,000 new cases Friday as the virus spreads fast in pockets around the nation, especially in the Midwest, according to data compiled by Johns Hopkins University and Bloomberg. The seven-day average has risen for five consecutive weeks. Another 962 deaths were reported Friday, down for the second day, the data show, amid a general decline in fatalities. The U.S. recorded 4 million vaccine doses on Friday, as the pace picked up again after the Easter and Passover holidays, according to the Bloomberg Vaccine Tracker. Italy Industry Lobby Cuts Growth Forecast Due to Virus Resurgence (7:53 a.m. NY)Italy’s biggest industrial lobby group cut its forecast for economic growth after a surge in infections in the country earlier this year.Confindustria now sees Italy’s economic growth at 4.1% this year, 0.7 percentage points below its October forecast, after the health crisis led to a weaker than expected performance in the final quarter of 2020 and first quarter of 2021. It said the new forecast hinges on progress in vaccinations in Italy and the rest of Europe. Norwegian Study Links Blood Clots to AstraZeneca Jab (6:53 a.m. NY)A Norwegian study into blood clots and abnormally low levels of platelets in five people who were given the AstraZeneca vaccine for Covid-19 has found that their condition was a vaccine-induced syndrome, according to an article in the New England Journal of Medicine.“By providing a link between thrombosis and the immune system, these results strengthen the view that vaccination may have triggered the syndrome,” the article cited the study as saying.Denmark and Norway are avoiding use of the Astra vaccine even though it’s been approved for use there, saying they need more time to review the risks. Sweden and Finland are only offering it to people over the age of 65.Europe Could Beat U.K. in Vaccination Target: Brussels (5:32 p.m. HK)Europe could have fully vaccinated 70% of adults before the U.K. reaches its own target of one dose for all over-18s by the end of July, Thierry Breton, the European commissioner leading Brussels’ vaccine task force, said in an interview with the Guardian.Europe was expecting 360 million doses from five manufacturers in the second quarter, with European factories set to produce 200 million shots a month by September for an overall capacity of 2 to 3 billion by year end. The “extremely rapid” increase in European production capacity should allow the EU’s 27 nations to compensate for first-quarter shortfalls and allow “an almost normal tourist season”, Breton said.Airline Body Wants U.K. to Probe Travel Test Pricing (5:05 p.m. HK)Global airline body IATA called on the U.K. Competition and Markets Authority to launch an inquiry into pricing of Covid-19 tests for travel, as separate research showed travelers had to pay twice as much for the PCR tests in Britain as they do in much of Europe, the Guardian reported on Sunday.While the cheapest U.K. pre-departure PCR tests are available for 60 pounds ($82) -- the subsidized rate for passengers at Gatwick Airport -- most travelers are being charged an average of 128 pounds, more than double the price for much of Europe, according to research from the Association of British Travel Agents and the Airport Operators Association.Jet2, one of the biggest tour operators in the U.K., postponed all holidays until June 23 citing lack of clarity from the government, the Guardian reported in a separate story. The tour operator said “not knowing when we can start to fly and where we can fly to” led to suspension of flights and holidays.EU’s Michel Sees Surge in Vaccinations After Early Stumbles (4:43 p.m. HK)European Council President Charles Michel expects the region to soon move past the shortfall in vaccine availability, and become a leading producer, he said in an interview with a range of newspapers including Germany’s Handelsblatt. Output will continue to grow in the coming weeks and Europe may even become the world’s biggest maker of inoculations.Germany reported 23,945 new Covid-19 cases in the last 24 hours, marking the third straight day of declines. Deaths fell to 246, down from 294 a day earlier.Russian Cases Are Still Falling, With Number of Deaths Stable (4:09 p.m. HK)Russia reported 8,704 new Covid-19 cases in the last 24 hours, down from the 9,150 reported a day earlier as the caseload continues to stabilize. Authorities reported 402 deaths yesterday from the virus, unchanged from the previous day.Pakistan Approves Sinovac Shot for Emergency Use (3:35 p.m. HK)Pakistan’s drug regulator approved Sinovac Biotech Ltd.’s vaccine for emergency use, Xinhua News Agency reported, citing the Drug Regulatory Authority of Pakistan. The move adds a third Chinese vaccine to Pakistan’s arsenal as the country faces a new wave on infections. Pakistan previously approved shots developed by Sinopharm and CanSino Biologics Inc.Tokyo Cases Top 500 Again (2:25 p.m. HK)Tokyo reported 570 additional infections on Saturday, topping 500 for a fourth straight day, and the daily number of virus cases in Osaka hit a record of 918, according to Kyodo News. Japan on Friday said it will reimpose restrictions in Tokyo, Kyoto and Okinawa, aiming to rein in a rapid spread of the coronavirus in those areas three weeks after ending a state of emergency in the capital.Thailand Sees Most Cases Since Early February (12:57 p.m. HK)Thailand reported 789 new cases, the highest since Feb. 4, bringing the total to 31,658 infections, according to the Health Ministry. Most cases are linked to entertainment venue clusters in the Thai capital. One new death was reported Saturday, raising the total to 97.India’s Hospitals Swamped by Second Wave (12:34 p.m. HK)India is facing an escalating health crisis, with its second wave of virus infections hitting record highs, overwhelming hospitals around the country as supplies of intensive care beds and vital drugs come under pressure.Across the South Asian nation, from the wealthiest and also the worst-hit state of Maharashtra to its most populous, Uttar Pradesh, reports are emerging of hospital beds running short and immunization centers turning away people as they run out of vaccines. India reported more than 145,000 new infections Saturday, and with over 13 million virus cases lags behind only the U.S. and Brazil.U.K. Urges Mourners Not to Gather (12:29 p.m. HK)U.K. officials urged people not to gather or lay flowers following the death of Prince Philip, Queen Elizabeth II’s husband, a sign of how longstanding traditions will have to be put aside due to the pandemic. Well-wishers congregated outside Buckingham Palace and laid floral tributes on Friday, following the news of the Duke of Edinburgh’s passing at Windsor Castle, west of London, at the age of 99.China Approves Third Sinopharm Shot for Trial (4:40 p.m. HK)China has approved the third vaccine from Sinopharm Group Co. to start clinical trials, the company said. The green light to begin testing comes after two inactivated vaccines from Sinopharm were approved and widely used both at home and in developing countries.China’s ambitious effort to vaccinate 560 million people -- 40% of its population -- by the end of June is nonetheless running into a supply shortage, forcing authorities to extend the intervals between doses and leaving some people unable to book second shots. China had administered 161.1 million doses of Covid vaccines as of Friday, the National Health Commission said in a statement.South Korea’s Moon Calls Meeting on Virus (11:32 a.m. HK)South Korean President Moon Jae-in will hold an urgent meeting on Monday with the country’s top health officials to review the response to the pandemic and discuss vaccine supplies, Yonhap News reported Saturday, citing a presidential spokesman.Health authorities warned this week that the country is in the early stage of another wave of infections. They also said they may consider stricter social distancing measures and curtail some business activities if the weekly average of cases rises. South Korea confirmed 677 more infections on Saturday.CureVac Could Win EU Shot Approval in May (10:04 a.m. HK)CureVac NV could win European Union approval for its vaccine as early as May, sooner than expected, a German newspaper cited a company spokesman as saying.“We’re already very far advanced in the third phase of clinical trials and are awaiting data for the final application package,” CureVac spokesman Thorsten Schueller told Augsburger Allgemeine. “We hope the approval will come in May or June.”CureVac’s boosters include Elon Musk, who deleted a Twitter post on Friday saying that the biotech sounded to be “a few months away from regulatory approval.”Covid Hampers St. Vincent Evacuation (7:33 a.m. HK)Covid-19 is hampering efforts to evacuate people from the eastern Caribbean island of St. Vincent, where the La Soufriere volcano began erupting Friday morning.St. Vincent and the Grenadines Prime Minister Ralph Gonsalves said efforts to move an estimated 20,000 residents who live near the volcano were underway. But the pandemic is causing delays. Hotels that are being turned into refugee centers are asking that people be vaccinated, a request that Gonsalves said was “not unreasonable.”WHO Chief: Political Will Missing for Equitable Vaccination (12:06 a.m. HK)A lack of political will and weak global solidarity are the “mother of all bottlenecks” to ensuring an equitable distribution of Covid-19 vaccines to low-income countries, World Health Organization Director-General Tedros Adhanom Ghebreyesus said.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
When you think about dividend stocks, it's very easy to simply look at the posted yield and figure that the best stocks have the highest yields. Dividend yield is one important piece of total return, but you can't leave out price growth. Here, we'll look at five dividend-paying stocks that have a proven track record of increasing their dividends as well as a strong position for price growth.
Bitcoin (CRYPTO: BTC) has surged in popularity, but it still seems like a mystery to many people. In this Fool Live video clip, recorded on March 18, senior analyst John Rotonti and Motley Fool Deutschland lead analyst Bernd Schmid discuss the basics of adding Bitcoin to your investment strategy. John Rotonti: So how do I buy Bitcoin?
The online gambling business has gotten a lot of attention from investors over the past year as betting has opened up in new markets and companies like DraftKings (NASDAQ: DKNG), Rush Street Interactive (NYSE: RSI), and Golden Nugget Online Gaming (NASDAQ: GNOG) have come public. The biggest is DraftKings, whose market cap is almost $25 billion, bigger than the more established MGM Resorts' (NYSE: MGM) $21 billion cap. MGM Resorts is trying to buck that trend with some large and lucrative partnerships.
At least six people were killed after a 6.0 magnitude quake struck off the coast of Indonesia's main Java island, its disaster agency said Saturday, as the country reels from a cyclone disaster in another part of the archipelago.
The oil industry has an awful track record of creating shareholder value over the past decade. While oil-price volatility is one culprit, capital allocation has been another major factor contributing to the sector's poor performance. Oil companies have a history of chasing growth by investing in drilling as many wells as possible.
Manchester City suffered just a fourth Premier League defeat of the season as 10-man Leeds United shocked the runaway leaders thanks to Stuart Dallas's double in a 2-1 win at the Etihad on Saturday.
French container shipping group CMA CGM is pursuing a plan to rebuild Beirut's port within three years, despite political deadlock in Lebanon that has prevented decisions on the port since a blast last August, a company executive said. A chemical explosion at the port killed 200 people and destroyed entire neighbourhoods, deepening Lebanon's worst political and economic crisis since the 1975-1990 civil war. CMA CGM's plan, first outlined to Lebanese authorities in September, envisages the reconstruction of damaged docks and warehouses, along with port expansion and digitalisation, at a total cost estimated at $400 million to $600 million, Joe Dakkak, general manager CMA CGM Lebanon, said on Saturday.
Two men who roamed the Indian capital using monkeys to rob unsuspecting victims have been arrested, New Delhi police said Saturday.
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of SOS Limited (“SOS” or the “Company”) (NYSE: SOS) from July 22, 2020, through February 25, 2021 (the “Class Period”). The lawsuit filed in the United States District Court for the District of New Jersey alleges violations of the Securities Exchange Act of 1934. If you purchased SOS securities, and/or would like to discuss your legal rights and options please visit SOS Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors: (i) SOS had misrepresented the true nature, location, and/or existence of at least one of the principal executive offices listed in its SEC filings; (ii) HY and FXK were either undisclosed related parties and/or entities fabricated by the Company; (iii) the Company had misrepresented the type and/or existence of the mining rigs that it claimed to have purchased; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. On February 26, 2021 Hindenburg Research (“Hindenburg”) and Culper Research (“Culper”) released commentary on SOS, claiming that the Company was an intricate “pump and dump” scheme that used fake addresses and doctored photos of crypto rigs to create an illusion of success. On this news, SOS’s American depositary share (“ADS”) price fell $1.27 per share, or 21.03%, to close at $4.77 per ADS on February 26, 2021. If you wish to serve as lead plaintiff, you must move the Court no later than June 1, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. If you purchased SOS securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/soslimited-sos-shareholder-class-action-lawsuit-stock-fraud-384/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years. ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information Matthew E. GuarneroBernstein Liebhard LLPhttps://www.bernlieb.com(877) 779-1414MGuarnero@bernlieb.com
Study Confirms F-star’s Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and ActivationCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that preclinical data from FS222, a potentially best-in-class tetravalent bispecific antibody targeting both CD137 and PD-L1 will be presented in a poster at the 2021 American Academy of Cancer Research (AACR) Annual Meeting, taking place virtually from April 10-15 and May 17-21. Poster #1864, entitled ‘FS222, a Tetravalent Bispecific Antibody Targeting CD137 and PD-L1, is Designed for Optimal CD137 Interactions Resulting in Potent T cell Activation Without Toxicity’ will be available via on-demand viewing starting today, April 10, at 8:30 a.m. ET. FS222 targets PD-L1, the immune checkpoint protein that regulates the balance of activated T cells in the immune system and is overexpressed on many solid tumors and CD137, a co-stimulatory molecule from the tumor necrosis factor receptor superfamily (TNFRSF), which is widely known to be upregulated on tumor-reactive CD8+ T cells or “killer T cells”. Currently, only a minority of patients have a long-lasting response to monotherapies that block the PD-(L)1 pathway. Neil Brewis, Chief Scientific Officer at F-star Therapeutics, said: “We are encouraged by the results of these latest preclinical studies of FS222, our tetravalent bispecific antibody targeting PD-L1 and CD137. This work further demonstrates that FS222’s tetravalent binding mechanism is the most efficient and effective format for bispecific antibodies. The early onset of activity and T cell proliferation gives us confidence that FS222 will allow for a wide range of treatment options.” FS222 was designed to be a potent human CD137/PD-L1 tetravalent conditional agonist with a unique combination of high affinity PD-L1 binding, and moderate affinity, but with high avidity, binding to CD137 on activated T cells to result in optimal receptor clustering. Previously, FS222 has been shown to exhibit a favorable safety profile in preclinical safety studies. Tetravalent binding by FS222 demonstrated optimal activity in multiple preclinical pharmacology studies, outperforming classic heterodimeric bispecific antibodies. These data showed that there was no evidence of a hook effect, or bell-shaped dose response curve, in vitro, and coupled with FS222’s favorable safety profile, presents a potentially broad and differentiated therapeutic window. A murine surrogate mAb2 for FS222 had peripheral immunopharmacology, as shown by CD8+ T cell proliferation, at high dose levels, mirroring the in vitro data, whereby the tetravalent FS222 surrogate mAb2 outperforms other lower valency formats. In January 2021, F-star announced that the first patient had been dosed in a Phase 1 clinical trial of FS222, a multicenter, open-label, first-in-human trial to evaluate the safety, tolerability, and early signs of efficacy of FS222 in adult patients diagnosed with advanced malignancies. The adaptive study design will allow for the early exploration of clinical activity of FS222 in a range of selected solid tumors that will guide future targeted clinical development. About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com and follow us on LinkedIn and Twitter. Forward Looking Statements Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. F-star undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including those discussed in F-star’s Annual Report on Form 10-K, as well as subsequent Quarterly Reports on Form 10-Q and other documents to be filed from time to time with the SEC. New factors emerge from time to time and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this communication are based on information available to F-star as of the date of this communication. F-star does not assume any obligation to update such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For further information, please contact: For investor inquiriesLindsey TrickettVP Investor Relations & Communications+1 240-543-7970lindsey.trickett@f-star.com For media inquiriesHelen ShikShik Communications LLC+1 617-510-4373Shik.Helen10@gmail.com
Melbourne United have reclaimed top spot on the NBL ladder after grinding out a tough 84-78 victory over New Zealand Breakers.United were far from their best but made a strong finish to Saturday's clash at John Cain Arena to return to the top of the NBL standings with a 16-5 win-loss record.
Greater Western Sydney have grabbed their first win of the season with a hard fought victory over Collingwood.
RADNOR, Pa., April 10, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Southern District of New York against Ebix, Inc. (NASDAQ: EBIX) (“Ebix”) on behalf of those who purchased or acquired Ebix securities between November 9, 2020 and February 19, 2021, inclusive (the “Class Period”). Investors who purchased or acquired Ebix securities during the Class Period may, no later than April 23, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at info@ktmc.com; or click https://www.ktmc.com/ebix-inc-securities-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=ebix Ebix supplies infrastructure exchanges to the insurance, financial, travel, cash remittances, and healthcare industries. The Class Period commences on November 9, 2020, when Ebix filed its quarterly report for the period ended September 30, 2020 on a Form 10-Q with the SEC, stating in relevant part that the “Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our ‘disclosure controls and procedures’ . . . [and] have concluded that these disclosure controls and procedures are effective.” On February 19, 2021, after the market closed, Ebix revealed that its independent auditor, RSM US LLP (“RSM”), resigned “as a result of being unable, despite repeated inquiries, to obtain sufficient appropriate audit evidence that would allow it to evaluate the business purpose of significant unusual transactions that occurred in the fourth quarter of 2020” related to Ebix’s gift card business in India. RSM also stated that there was a material weakness related to Ebix’s failure to design controls “over the gift or prepaid card revenue transaction cycle sufficient to prevent or detect a material misstatement.” Additionally, Ebix and RSM disagreed over the accounting treatment of $30 million that had been transferred into a commingled trust account of Ebix’s outside legal counsel in December 2020. Following this news, Ebix’s share price fell $20.24, or approximately 40%, to close at $30.50 on February 22, 2021. The complaint alleges that, throughout the Class Period, the defendants failed to disclose to investors that: (1) there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix’s gift card business in India during the fourth quarter of 2020; (2) there was a material weakness in Ebix’s internal control over the gift or prepaid revenue transaction cycle; (3) Ebix’s independent auditor, RSM, was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix’s outside legal counsel; and (4) as a result of the foregoing, the defendants’ positive statements about Ebix’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Ebix investors may, no later than April 23, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer & Check, LLPJames Maro, Jr., Esq.Adrienne Bell, Esq.280 King of Prussia RoadRadnor, PA 19087(844) 887-9500 (toll free)info@ktmc.com
Yahoo Finance